Registry for cardiac PYP scans in patients with heart failure and amyloidosis in Taiwan
A Multi-center Registry for Clinical Information and 99mTc-pyrophosphate Scintigraphy in Patients With Suspected Cardiac Amyloidosis in Taiwan
This study is collecting and analyzing data from patients in Taiwan with heart failure and suspected cardiac amyloidosis to see if PYP scans can help diagnose the condition better than traditional methods.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | Far Eastern Memorial Hospital Academic / other |
| Locations | 1 site (New Taipei City) |
| Trial ID | NCT05593679 on ClinicalTrials.gov |
What this trial studies
This project aims to collect and analyze data from patients suspected or diagnosed with cardiac amyloidosis (CA) through PYP scans at medical centers in Taiwan. It will involve both retrospective and prospective data collection, focusing on patients with specific clinical signs and imaging results. The study will evaluate the quality of imaging and the correlation between clinical parameters and PYP scan results, potentially replacing invasive procedures like myocardial biopsy. The goal is to enhance understanding of CA and improve diagnostic strategies.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 20 and older with a documented diagnosis or suspicion of ATTR amyloidosis.
Not a fit: Patients with significant systemic diseases or those who refuse clinical follow-up may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier diagnosis and better treatment strategies for patients with cardiac amyloidosis.
How similar studies have performed: While there is limited large-scale clinical data on this specific approach, the use of PYP scans in diagnosing cardiac amyloidosis has shown promise in smaller studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. ≥ 20 years of age 2. Documented diagnosis or r/o of ATTR amyloidosis Exclusion Criteria: 1. Pregnant or nursing (lactating) women. 2. Important systemic diseases (except heart disease or neurological diseases) such as liver cirrhosis, active malignant tumors, etc., with a life expectancy of less than 6 months. 3. Patient who refused clinical follow up.
Where this trial is running
New Taipei City
- Far Eastern Memorial Hospital — New Taipei City, Taiwan (Recruiting)
Study contacts
- Principal investigator: Yen-Wen Wu — Far Eastern Memorial Hospital
- Study coordinator: Yen-Wen Wu
- Email: wuyw0502@gmail.com
- Phone: 886-2-8966-7000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.